ライフサイエンスコーパス: fatty acid synthase

1 s of lipogenesis, acetyl CoA carboxylase and fatty acid synthase.

2 and highly selective inhibitor of mammalian fatty acid synthase.

3 id synthesis genes acetyl CoA carboxylase or fatty acid synthase.

4 combinant form of the thioesterase domain of fatty acid synthase.

5 demonstrated with acetyl-CoA carboxylase and fatty acid synthase.

6 ruvate kinase, acetyl-CoA carboxylase 1, and fatty acid synthase.

7 hydroxy-3-methylglutaryl CoA reductase), and fatty acid synthase.

8 oacyl synthase domain of the human cytosolic fatty acid synthase.

9 y-terminal thioesterase domain of the animal fatty acid synthase.

10 f both hepatic stearoyl CoA desaturase-1 and fatty acid synthase.

11 nt fatty acid product derived from mammalian fatty acid synthase.

12 o of its targets, acetyl-CoA carboxylase and fatty acid synthase.

13 the expression of acetyl-CoA carboxylase and fatty acid synthase.

14 tease serine 2, FK506-binding protein 51 and fatty acid synthase.

15 compared to the homologous dimeric mammalian fatty acid synthase.

16 ol regulatory element-binding protein 1c and fatty acid synthase.

17 ibits up-regulation of ATP citrate lyase and fatty-acid synthase.

18 acids are synthesized by type I and type II fatty acid synthases.

19 ta-ketoacyl-ACP synthase activity of type II fatty acid synthases.

20 acyl thioesters generating novel short-chain fatty acid synthases.

21 products that target bacterial and mammalian fatty acid synthases.

22 atory element-binding protein 1c target gene fatty-acid synthase (3.0-fold), early growth response-1

23 and 18-carbon fatty acids is carried out by fatty acid synthase, a 2.6 megadalton molecular-weight m

24 acid synthetic genes, including Srebp-1 and fatty acid synthase, a pathway previously shown to be in

25 r, to the acyl carrier protein domain of the fatty acid synthase, a thioesterase active toward shorte

26 macologic inhibition of Rho, glutaminase, or fatty acid synthase abrogated the increased lipid conten

27 ory element-binding transcription factor 1c, fatty acid synthase, acetyl coenzyme A carboxylase 2, an

28 of the key enzymes involved in lipogenesis: fatty acid synthase, acetyl-CoA carboxylase 1, and glyce

29 r RNA levels of the hepatic lipogenic genes, fatty acid synthase, acetyl-CoA carboxylase, and stearoy

30 cells, the mRNA levels of SREBP1-c, SREBP2, fatty-acid synthase, acetyl-CoA carboxylase, ATP citrate

31 ction of apoptosis in VarK-infected MCC with fatty acid synthase-activating antibody significantly en

32 thioesterase domain and resulted in reduced fatty acid synthase activity and an increase in product

33 We traced this defect to the uncoupling of fatty acid synthase activity from stearoyl-CoA desaturas

34 romotes insulin clearance and down-regulates fatty acid synthase activity in the liver upon its phosp

35 kinases, but requires protein synthesis and fatty acid synthase activity.

36 diates a negative acute effect of insulin on fatty acid synthase activity.

37 leptin resistance and elevated hypothalamic fatty-acid synthase activity could underlie altered ener

38 Hypothalamic fatty-acid synthase activity is also elevated in the mut

39 Ablation of type II fatty-acid synthase activity resulted in reduced intrace

40 with type I polyketide synthases and related fatty-acid synthases also extends to the interdomain con

41 ferator-activated receptor gamma, Glut4, and fatty acid synthase, although cells overexpressing IR re

42 de-1-beta-D-ribofuranoside) enhanced and the fatty acid synthase-AMPK inhibitor C75 (3-carboxy-4-octy

43 ovel inhibitor of the thioesterase domain of fatty acid synthase, an enzyme strongly linked to tumor

44 s, which correlates with increased levels of Fatty Acid Synthase and Acetyl CoA Carboxylase mRNAs, en

45 ly increased the hepatic protein contents of fatty acid synthase and acetyl-coenzyme A carboxylase (A

46 ocess by application to the Escherichia coli fatty acid synthase and apply it to probe protein-protei

47 wnregulation of stearoyl CoA desaturase-1 or fatty acid synthase and by upregulation of hepatic chole

48 Based on recent evidence that fatty acid synthase and endogenously produced fatty acid

49 l activation of lipogenic enzymes, including fatty acid synthase and glycerol-3-phosphate acyltransfe

50 lipogenic genes, acetyl CoA carboxylase, and fatty acid synthase and increasing the expression of bet

51 L1 adipocytes resulted in a decrease of both fatty acid synthase and insulin receptor substrate-1 pro

52 of utilization and degradation catalyzed by fatty acid synthase and malonyl-CoA decarboxylase, respe

53 ces secretion of several proteins, including fatty acid synthase and metastasis-associated laminins.

54 ecently have been implicated in induction of fatty acid synthase and other genes.

55 the catalytic domains of multidomain type I fatty acid synthase and polyketide synthase (PKS) system

56 everal proadipogenic genes, adiponectin, and fatty acid synthase and reduced the expression of inflam

57 Fatty acid synthase and steaoryl-coenzyme A desaturase,

58 enes involved in lipid metabolism, including fatty acid synthase and steroyl coenzyme-A desaturase, t

59 omain of the human cytosolic multifunctional fatty acid synthase and the acyl carrier protein associa

60 the study reveal unappreciated links between fatty acid synthase and ubiquitin-dependent proteolysis

61 ective inhibitors of bacterial and mammalian fatty acid synthases and have emerged as promising drug

62 rved among acyl carrier proteins involved in fatty acid synthases and polyketide synthases, a detaile

63 mRNA, PPARgamma2 protein, and mRNA levels of fatty-acid synthase and acetyl-CoA carboxylase.

64 ail is synthesized by the combined action of fatty-acid synthase and desaturases most likely in the p

65 Expression of fatty-acid synthase and SCD1 was decreased in FA2H-deple

66 two SREBP-1c-regulated lipogenic genes, e.g. fatty-acid synthase and the S14 protein in primary hepat

67 arboxylase), elevation in expression of FAS (fatty acid synthase), and lipid accumulation in human He

68 expression, further inducing PCSK9, SREBP-1, fatty acid synthase, and apoB mRNA.

69 n of beta-catenin, p53, p21, p27, cyclin D1, fatty acid synthase, and cyclooxygenase-2.

70 ated receptor gamma, adiponectin, perilipin, fatty acid synthase, and lipoprotein lipase.

71 n the acyltransferase (AT) domains of DynE8, fatty acid synthase, and modular polyketide synthases, w

72 De novo lipogenesis requires fatty acid synthase, and recent studies of this enzyme s

73 ydroxy-3-methylglutaryl-coenzyme A synthase, fatty acid synthase, and stearoyl-CoA desaturase.

74 y role between malonyl-CoA, the substrate of fatty acid synthase, and the neural circuitry regulating

75 or 3-hydroxy-3-methylglutaryl-CoA reductase, fatty-acid synthase, and squalene synthase in livers of

76 y lipogenic enzymes, acetyl-CoA carboxylase, fatty-acid synthase, and stearoyl-CoA desaturase-1 were

77 Individual subunits of fatty acid synthase are proteolytically degraded when th

78 regulation of lipogenic enzymes SREBP-1c and fatty acid synthase, as well as increased hepatic lipid

79 ifunctional enzymes that resemble eukaryotic fatty acid synthases but can make highly functionalized

80 Furthermore, KGF increased protein levels of fatty acid synthase, C/EBPalpha, C/EBPdelta, SREBP-1, ep

81 ular administration of a potent inhibitor of fatty acid synthase, C75, increases the level of its sub

82 trol encoding, for example, the cyclopropane fatty acid synthase, Cfa, the glycogen synthesis protein

83 especially the potential role of specialised fatty acid synthase complexes.

84 The type II fatty acid synthase consists of a series of individual e

85 issue indicated that nuclear localization of fatty acid synthase correlates with Gleason grade, impli

86 ketide synthase that uniquely incorporates a fatty acid synthase-derived dichloropyrrolyl extender un

87 biochemical regulators of bacterial type II fatty acid synthases due to their ability to feedback-in

88 c markers (aP2, CD36, and perilipin) and low fatty-acid synthase enzymatic activity.

89 ma gondii enoyl reductase (TgENR), a type II fatty acid synthase enzyme essential in parasites but no

90 l similarity between polyketide synthase and fatty acid synthase enzymology.

91 In addition, increased fatty acid synthase expression in prostate cancer correl

92 9), (11)C-acetate uptake was independent of fatty acid synthase expression using immunohistochemistr

93 Fatty acid synthase expression was also increased in the

94 Further, leptin decreased perilipin and fatty acid synthase expression, which play an important

95 eptococcus pneumoniae, the expression of the fatty acid synthase (fab) genes is controlled by a helix

96 III (KSIII) AsuC3/C4 as well as the cellular fatty acid synthase FabH to produce the asukamycin conge

97 els in E1 and E4-mice were linked to reduced fatty acid synthase (FAS) activity and hepatic expressio

98 f nicotine increased lipolysis and inhibited fatty acid synthase (FAS) activity in a time- and dose-d

99 Fatty acid synthase (FAS) activity is a potential therap

100 levels for various lipogenic enzymes such as fatty acid synthase (FAS) and acetyl-CoA carboxylase (AC

101 sis as reflected by increased mRNA levels of fatty acid synthase (Fas) and acetyl-CoA carboxylase (Ac

102 ly by overexpression and/or hyperactivity of fatty acid synthase (FAS) and acetyl-CoA carboxylase (AC

103 arrier proteins (ACPs) are essential to both fatty acid synthase (FAS) and polyketide synthase (PKS)

104 Activation of AKT and overexpression of fatty acid synthase (FAS) are frequently observed in hum

105 Eukaryotes and prokaryotes possess fatty acid synthase (FAS) biosynthetic pathways that com

106 Fatty acid synthase (FAS) catalyzes the synthesis of pal

107 monstrate that R activates expression of the fatty acid synthase (FAS) cellular gene through a p38 st

108 atty acid chain between enzymatic domains of fatty acid synthase (FAS) during biosynthesis.

109 Liver X receptor (LXR) activates fatty acid synthase (FAS) gene expression through bindin

110 related with its inability to increase liver fatty acid synthase (FAS) gene expression, which was up-

111 The fatty acid synthase (FAS) gene is significantly up-regul

112 el of intrauterine growth restriction due to fatty acid synthase (FAS) haploinsufficiency (FAS deleti

113 Fatty acid synthase (FAS) has been found to be overexpre

114 Fatty acid synthase (FAS) has been found to be overexpre

115 High levels of fatty acid synthase (FAS) have been found in cancer prec

116 atory element-binding protein (Srebp) 1c and fatty acid synthase (Fas) in the liver.

117 Inhibition of fatty acid synthase (FAS) induces a rapid decline in fat

118 Fatty acid synthase (FAS) inhibition initiates selective

119 The central administration of the fatty acid synthase (FAS) inhibitor, C75, rapidly suppre

120 C75, a fatty acid synthase (FAS) inhibitor, causes weight loss

121 Fatty acid synthase (FAS) inhibitors, administered syste

122 Fatty acid synthase (FAS) is a central enzyme in lipogen

123 Overexpression of the lipogenic enzyme fatty acid synthase (FAS) is a common molecular feature

124 Human fatty acid synthase (FAS) is a large, multidomain protei

125 Fatty acid synthase (FAS) is necessary for growth and su

126 In eukaryotes, fatty acid synthase (FAS) is the enzyme responsible for

127 tent inhibitor of the thioesterase domain of fatty acid synthase (FAS) led us to develop a concise an

128 Mevalonate depletion increased fatty acid synthase (FAS) mRNA by transcriptional mechan

129 feeding-dependent regulation of SREBP-1c and fatty acid synthase (FAS) mRNA expression in the transit

130 Evidence links the hypothalamic fatty acid synthase (FAS) pathway to the regulation of f

131 Fatty acid synthase (FAS) promotes energy storage throug

132 Unexpectedly, the lipogenic enzyme fatty acid synthase (FAS) was increased in the skeletal

133 Fatty acid synthase (FAS), a key enzyme of the fatty aci

134 tween autophagy-related protein 8 (Atg8) and fatty acid synthase (FAS), a pivotal enzymatic complex r

135 Endogenous fatty acid synthesis, mediated by fatty acid synthase (FAS), affects membrane composition.

136 We show that fatty acid synthase (FAS), an insulin-responsive enzyme

137 or of lipid metabolism by inducing SREBP-1c, fatty acid synthase (FAS), and acetyl-CoA carboxylase (A

138 ncluding choline kinase alpha (ChoK(alpha)), fatty acid synthase (FAS), and phosphorylated ATP-citrat

139 : hydroxymethylglutaryl-CoA reductase (Red), fatty acid synthase (FAS), and squalene synthase (SQS).

140 The associations of OGA with fatty acid synthase (FAS), filamin-A, heat shock cognate

141 ing protein (aP2), lipoprotein lipase (LPL), fatty acid synthase (FAS), hormone sensitive lipase (HSL

142 nistration of C75, a potent inhibitor of the fatty acid synthase (FAS), increases malonyl-CoA concent

143 C75, an inhibitor of fatty acid synthase (FAS), induces apoptosis in cultured

144 s is de novo synthesis, which is mediated by fatty acid synthase (FAS), ingested food, or both.

145 C75, a synthetic inhibitor of fatty acid synthase (FAS), is hypothesized to alter the

146 Pharmacological inhibition of fatty acid synthase (FAS), rate limiting for de novo lip

147 es involved in fatty acid synthesis, such as fatty acid synthase (FAS), sterol receptor element bindi

148 ional activators of lipogenic genes, such as fatty acid synthase (FAS), sterol regulatory element-bin

149 expression is impaired with inactivation of fatty acid synthase (FAS), suggesting that FAS is involv

150 Fatty acid synthase (FAS), the cellular enzyme that synt

151 Fatty acid synthase (FAS), the enzyme responsible for th

152 nd SREBP-2 proteins as well as expression of fatty acid synthase (FAS), the key regulatory enzyme in

153 Fatty acid synthase (FAS), the sole mammalian enzyme cap

154 er cells respond to inhibition of the enzyme fatty acid synthase (FAS), we focused on NF-kappaB-media

155 e of the HER2-regulated genes discovered was fatty acid synthase (FAS), which has been shown to be ov

156 ing of 5-10 standalone domains homologous to fatty acid synthase (FAS).

157 m glucose include ATP-citrate lyase (CL) and fatty acid synthase (FAS).

158 bility to inhibit the thioesterase domain of fatty acid synthase (FAS).

159 In this assay, ACC is coupled to fatty acid synthase (FAS).

160 and its targets acetyl-CoA carboxylase-1 and fatty acid synthase (FAS).

161 ic enzymes, acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS).

162 e of the 33 kDa thioesterase domain of human fatty acid synthase (FAS-TE).

163 produced via a combination of type I and II fatty acid synthases (FAS) with FAS-I products being elo

164 Nonribosomal peptide synthetases (NRPS), fatty acid synthases (FAS), and polyketide synthases (PK

165 Among bacterial fatty acid synthases (FAS), the Escherichia coli FAS is

166 Like fatty acid synthases (FAS), these enzymes are organized

167 Mycobacteria possess two fatty acid synthases (FAS); FAS-I carries out de novo sy

168 e elongation systems, the type I and type II fatty acid synthases (FAS-I and FAS-II respectively).

169 primary lipogenic target enzymes, including fatty-acid synthase (FAS) and acetyl-CoA carboxylase 1 (

170 esis affects atherosclerosis, we inactivated fatty-acid synthase (FAS) in macrophages of apoE-deficie

171 Fatty-acid synthase (FAS) is up-regulated in a broad ran

172 process driven by the multifunctional enzyme fatty-acid synthase (FAS), maintains endothelial functio

173 sms underlying transcriptional activation of fatty-acid synthase (FAS), we examined the relationship

174 by competing with the enzymes of the type II fatty acid synthase (FASII) cycle for the beta-hydroxyac

175 n-regulating their targeted genes, including fatty acid synthase (FASN) and 3-hydroxy-3-methylglutary

176 Fatty acid synthase (FASN) and ATP-citrate lyase, key en

177 onist CL316,243 (CL) increased expression of fatty acid synthase (FASN) and medium chain acyl-CoA deh

178 We observed a significant increase in fatty acid synthase (FASN) expression with increasing di

179 Five tagging polymorphisms in the fatty acid synthase (FASN) gene (rs1127678, rs6502051, r

180 Fatty acid synthase (FASN) is a key lipogenic enzyme cat

181 Fatty acid synthase (FASN) is a lipogenic enzyme that is

182 Fatty acid synthase (FASN) is an emerging tumor-associat

183 Fatty acid synthase (FASN) is physiologically regulated

184 The type I fatty acid synthase (FASN) is responsible for the de nov

185 riven hepatocarcinogenesis using conditional Fatty Acid Synthase (FASN) knockout mice.

186 and elevated levels of the lipogenic enzyme fatty acid synthase (FASN) mark those tumors.

187 one acetylation and amounts of rate-limiting fatty acid synthase (Fasn) mRNA.

188 FAMIN formed a complex with fatty acid synthase (FASN) on peroxisomes and promoted f

189 5LO/LTB4 inhibition reduced fatty acid synthase (FASN) promoter activity and its exp

190 Fatty acid synthase (FASN) regulates de novo lipogenesis

191 al genetic and pharmacological inhibition of fatty acid synthase (FASN) suppresses toxicity induced b

192 Blockade of fatty acid synthase (FASN), a key enzyme involved in de

193 ynthesis resulted from the downregulation of fatty acid synthase (FASN), a key regulator of fatty aci

194 ng up-regulation of lipid synthesis enzymes [fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC)

195 ic enzymes [acetyl CoA carboxylase 1 (ACC1), fatty acid synthase (FASN), and stearoyl CoA desaturase

196 nkage disequilibrium in 17q25.3, which spans fatty acid synthase (FASN), coiled-coil-domain-containin

197 revealed that a key enzyme in this pathway, fatty acid synthase (FASN), is relocalized to sites of D

198 (ChREBP, a master lipogenic regulator), and fatty acid synthase (FASN), its effector lipogenic gene.

199 Fatty acid synthase (FASN), the enzyme responsible for d

200 Inhibition or knockdown of fatty acid synthase (FASN), the enzyme that catalyzes th

201 c model of myocardium-specific expression of fatty acid synthase (FASN), the major palmitate-synthesi

202 he HCV genotype 2a (JFH1) virus, among which fatty acid synthase (FASN), the multifunctional enzyme c

203 Fatty acid synthase (FASN), the sole cytosolic mammalian

204 ein 1c (SREBP-1c) and its downstream target, fatty acid synthase (FASN), which are key proteins invol

205 sis gene signature and specific induction of fatty acid synthase (FASN).

206 and polyketide biosynthesis, and most of the fatty acid synthases (FASs) and polyketide synthases (PK

207 ichment, and identification of DH enzymes in fatty acid synthases (FASs) and polyketide synthases (PK

208 de synthases (PKSs) use chemistry similar to fatty acid synthases (FASs), although building block var

209 e I polyketide synthases (PKSs), and related fatty acid synthases (FASs), represent a large group of

210 armacological proof of concept of inhibiting fatty acid synthase for the treatment of diabetes and re

211 site serine residue, or functionality of the fatty acid synthase; further shortening of the linker li

212 an be explained by the apparent absence of a fatty acid synthase gene.

213 indicates that the lipogenic "overshoot" for fatty-acid synthase gene expression known to occur durin

214 did not affect expression of the specialized fatty acid synthase genes (stcJ and stcK) or polyketide

215 amma), CCAAT/enhancer-binding protein alpha, fatty acid synthase, glucose transporter 4, and the tran

216 Human fatty acid synthase (hFAS) is a homodimeric multidomain

217 The human fatty-acid synthase (HFAS) is a potential target for ant

218 que carboxyl terminal thioesterase domain of fatty acid synthase hydrolyzes the growing fatty acid ch

219 ulatory element-binding protein-1 (SREBP-1), fatty acid synthase, hydroxy-3-methylglutaryl coenzyme A

220 locks for de novo fatty acid biosynthesis by fatty acid synthase I (FAS I) and for the elongation of

221 ly, EchA6 interacts with selected enzymes of fatty acid synthase II (FAS-II) in bacterial two-hybrid

222 Inhibition or inactivation of InhA, a fatty acid synthase II (FASII) enzyme, leads to mycobact

223 Also, the up-regulation of human fatty acid synthase in a variety of cancer makes the thi

224 PKD1L2 primarily associates with endogenous fatty acid synthase in normal skeletal muscle, and these

225 te carboxykinase, glucose-6-phosphatase, and fatty acid synthase in ob/ob mice.

226 xylase content and higher gene expression of fatty acid synthase in the liver indicated reduced fatty

227 t binding protein-1, acetyl-CoA carboxylase, fatty acid synthase) in the group with high VAT/(VAT+SAT

228 ciated enzymes, acetyl-CoA carboxylase-1 and fatty acid synthase, in the liver and hypothalamus.

229 and 18 carbon fatty acids is carried out by fatty acid synthase: in yeast Saccharomyces cerevisiae,

230 other catabolic signals such as feeding and fatty acid synthase inhibition may also activate POMC ne

231 efect is recapitulated by treatment with the fatty acid synthase inhibitor cerulenin and is rescued b

232 from mice that were fed or injected with the fatty acid synthase inhibitor cerulenin were examined fo

233 ulnificus disease, was hypersensitive to the fatty acid synthase inhibitor cerulenin, showed aberrant

234 intake caused by i.c.v.-administered C75, a fatty acid synthase inhibitor that increases hypothalami

235 In contrast, the fatty-acid synthase inhibitor cerulenin nearly completel

236 the glycolytic inhibitor, 2-deoxyglucose, or fatty acid synthase inhibitors to perturb the metabolic

237 es with KasA, a key component of the type II Fatty Acid Synthase involved in mycolic acid synthesis.

238 Human fatty acid synthase is a large homodimeric multifunction

239 Because fatty acid synthase is expressed at low levels in normal

240 Fatty acid synthase is normally found in the cytosol; ho

241 As the females then enter diapause, fatty acid synthase is only sporadically expressed, and

242 the acyl chain, the overall integrity of the fatty acid synthase is quite tolerant to moderate change

243 Fatty acid synthase is up-regulated in a variety of canc

244 y acid biosynthesis by a type II dissociated fatty acid synthases is catalyzed by 3-ketoacyl-acyl car

245 yzed by both polyketide synthases (PKSs) and fatty acid synthases is most often carried out by a thio

246 ted with the accumulation of lipid reserves (fatty acid synthase) is highly up-regulated.

247 lecular features including cyclooxygenase 2, fatty acid synthase, KRAS, BRAF, PIK3CA, p53, p21, beta-

248 and the stimulation of ATP citrate lyase and fatty-acid synthase leading to de novo lipogeneis.

249 reased hyperinsulinemia-induced hypothalamic fatty acid synthase levels and activity.

250 Likewise, treatment with the fatty acid synthase/lipolysis inhibitor orlistat also se

251 We identify a fatty acid synthase mFAS (CG3524) responsible for mbCHC

252 ly, inhibitors of acetyl CoA carboxylase and fatty acid synthase mimicked leptin's action.

253 yl-CoA activation module; and the downstream fatty acid synthase module.

254 the upstream acetyl coenzyme A formation and fatty acid synthase modules enabled further production i

255 Fatty acid synthase mRNA levels were not altered but ace

256 nic enzymes, including a >2-fold increase in fatty acid synthase mRNA, protein, and activity, there w

257 cyl carrier protein (mtACP) of mitochondrial fatty acid synthase (mtFAS).

258 netic and nucleotide binding measurements on fatty acid synthases mutated in either of the two nucleo

259 Up-regulation of fatty acid synthase not only increases production of fat

260 ion of genes coding for a putative cytosolic fatty acid synthase of type 1 (FAS1) and polyketide synt

261 ) and the down-regulation of the chloroplast fatty acid synthase of type 2 (FAS2).

262 Deletion of fatty acid synthase or acetyl-CoA carboxylase (ACC) 1 in

263 By virtue of its ability to inhibit fatty acid synthase, Orlistat halts tumor cell prolifera

264 mponents of a putative type II mitochondrial fatty acid synthase pathway have been identified in huma

265 tein synthase (KAS) enzymes in the bacterial fatty acid synthase pathway.

266 ylcholine, which is blocked by inhibitors of fatty-acid synthase, PI 3-kinase, mTORC, or an antibody

267 t are widely used as inhibitors of mammalian fatty acid synthase, platensimycin specifically inhibits

268 rol regulatory element-binding protein 1 and fatty acid synthase protein levels in epididymal WAT of

269 Analysis of the fatty acid synthase protein sequence indicated the prese

270 In this regard, the type I animal fatty acid synthase resembles its type II counterpart in

271 and enoyl reductase components of the animal fatty acid synthase responsible for the reduction of the

272 sruption of the apicoplast-localized type II fatty-acid synthase resulted in greatly reduced synthesi

273 ta-oxidation, augmentation of translation of fatty acid synthase resulting in de novo lipogenesis, an

274 en the entire linker region was deleted, the fatty acid synthase retained 28% activity.

275 The acyl carrier protein (ACP) from fatty acid synthases sequesters elongating products with

276 Engineering a hybrid fatty acid synthase shifted the free fatty acids to a me

277 ession of genes involved in lipid synthesis (fatty acid synthase, squalene epoxidase, hydroxy-methylg

278 hesis genes, namely, acetyl-CoA carboxylase, fatty acid synthase, SREBP1c, chREBP, glucokinase, and p

279 involved in the de novo lipogenesis, such as fatty-acid synthase, stearoyl-CoA desaturase (SCD)-1, an

280 d lipolysis, as well as in the expression of fatty acid synthase, sterol regulatory element-binding p

281 necrosis factor-alpha, adiponectin, leptin, fatty acid synthase, sterol regulatory element-binding p

282 rted lower resolution, 4.5-Angstrom model of fatty acid synthase structure, and emphasizes the close

283 iated with a deficiency in the mitochondrial fatty acid synthase system, namely depleted lipoylation

284 of the bacterial and eukaryotic multienzyme fatty acid synthase systems offer the prospect of inhibi

285 the conserved reaction chemistry of various fatty acid synthase systems, the individual isozymes tha

286 on of fas, which encodes the multifunctional fatty acid synthase that supports phospholipid and trigl

287 with the DH of the highly related animalian fatty acid synthase, the DH monomer possesses a double-h

288 The 2.6-A resolution structure of human fatty acid synthase thioesterase domain reported here is

289 ses have been studied, including the soluble fatty acid synthases, those involved in polyketide synth

290 n 1c (SREBP-1c), acetyl-CoA carboxylase, and fatty-acid synthase, three key functions in the lipogeni

291 CPS is sufficiently different from the human fatty acid synthase to justify the development of novel

292 tudies presented here show that cyclopropane fatty acid synthase transcription induced by neutral ace

293 of carcinogen-treated versus untreated mice: fatty acid synthase, transketolase, pulmonary surfactant

294 an inhibition of the dehydratase step of the fatty-acid synthase type II elongation cycle.

295 suppressing the expression (and activity) of fatty acid synthase via a nonclassical pathway dependent

296 udies to probe the mechanism of cyclopropane fatty acid synthase via use of the onium chalcogens of A

297 EBP1 target genes acetyl-CoA carboxylase and fatty-acid synthase was suppressed, along with suppresse

298 ol regulatory element-binding protein 1c and fatty acid synthase, were detected in the livers of Adip

299 bitor of the condensing reactions of type II fatty acid synthase, were synthesized and evaluated for

300 oblast growth factor 21, interleukin-10, and fatty acid synthase, which are all regulated by nuclear